To clarify whether MAP2K1/2 mutations are a predictive or prognostic biomarker, analysis of the data obtained from the TCGA database was performed, based on the MAP2K1/2 mutational status of melanoma patients. The gene discussed is MAP2K1; the disease is melanoma.